Arkolith/Insider Trading/NAMS/Form 4

Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Sep 10, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.9M
Net Open-Market Flow
-$3.9M
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 9, 2025Sell(S)97K$26.11$2.5M15K
Sep 9, 2025Option exercise(M)150K$10.00$1.5M165K
Sep 9, 2025Sell(S)53K$25.31$1.3M112K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 9, 2025Option exercise(M)150K—$0280K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-114033) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML